PRESS RELEASE : Vivoryon Therapeutics N V : Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO
ImCheck Therapeutics SASApril 15, 2021 GMT
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer
Marseille, France, April 15, 2021 – ImCheck Therapeutics today announced the appointment of Loui Madakamutil, PhD, as Chief Scientific Officer (CSO). Dr. Madakamutil brings over 20 years of experience in developing transformative therapies that harness the immune system, having served in senior research and development positions in global biopharmaceutical companies including Nektar Therapeutics, Janssen, Takeda and Celgene. He will be responsible for advancing ImCheck’s extensive portfolio of novel preclinical-stage antibodies designed to engage the butyrophilin (BTN) superfamily of immune modulators with the potential to treat cancer, infectious and au
Expansion study planned upon definition of recommended dose to gather additional data Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company
MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment
MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition. The studies combine pre-clinical research conducted at the Wistar Institute as well as biomarker analysis of the previously completed OUTREACH clinical trial. MTL-CEBPA is the first candidate from MiNA s pipeline of small activating RNA therapeutics, a new class of medicines to restore normal cell function. The data will be presented during a poster session at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually from April 10 April 15, 2021.